en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2024
vol. 99
 
Share:
Send email
Share:
abstract:
Guidelines/recommendations

Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant

Teresa Jackowska
1, 2
,
August Wrotek
2
,
Iwona Beń-Skowronek
3
,
Łukasz Dembiński
4
,
Tomasz Jarmoliński
5
,
Artur Mazur
6
,
Anna Medyńska
7
,
Katarzyna Plata-Nazar
8
,
Jan Styczyński
9
,
Tomasz Szczepański
10
,
Ewa Toporowska-Kowalska
11
,
Piotr Hartmann
12
,
Hanna Czajka
13
,
Jarosław Peregud-Pogorzelski
14

  1. President of the Polish Paediatric Society
  2. Department of Paediatrics, Medical Centre for Postgraduate Education, Warsaw, Poland
  3. Department of Paediatric Endocrinology and Diabetology, Medical University of Lublin, Lublin, Poland
  4. Department of Gastroenterology and Infant Nutrition, Warsaw Medical University, Warsaw, Poland
  5. Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Medical University of Piastów Śląski, Wrocław, Poland
  6. Department of Paediatrics, Endocrinology and Paediatric Diabetology, Medical University of Rzeszów, Rzeszów, Poland
  7. Department of Paediatric Nephrology, Medical University of Piastów Śląski, Wroclaw, Poland
  8. Department of Paediatrics, Gastroenterology, Allergology and Infant Nutrition, Medical University of Gdańsk, Gdańsk, Poland
  9. Department of Paediatrics, Haematology and Oncology, A. Jurasz University Hospital No. 1, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
  10. Clinic of Paediatrics, Haematology and Paediatric Oncology, Zabrze, Silesian Medical University, Katowice, Poland
  11. Department of Paediatric Allergology, Gastroenterology and Nutrition, Medical University, Łódź, Poland
  12. Clinical Department of Paediatrics with Division of Allergology, Endocrinology, Neurology – Warsaw Children’s Hospital, Dziekanów Leśny, Poland
  13. College of Medical Sciences, University of Rzeszów, Rzeszów, Poland
  14. Department of Paediatrics, Oncology and Children’s Immunology, Pomeranian Medical University, Szczecin, Poland
Pediatr Pol 2024; 99 (4): 275-282
DOI: https://doi.org/10.5114/polp.2024.146429
Online publish date: 2024/12/30
View full text Get citation
 
PlumX metrics:
Respiratory syncytial virus (RSV) is one of the most important etiological agents of acute lower respiratory tract infections in children (LRTI-RSV). RSV infection occurs in almost all children during the first 2 years of life. RSV is one of the main causes of hospitalisation in the first year of life and especially in the first months of life.

In Poland, the monoclonal antibody palivizumab (Synagis) is currently available to protect infants against RSV as part of a drug programme. It is provided exclusively for premature infants and children at risk and should be administered monthly during the RSV season.

Two new methods of prophylaxis against RSV infection are currently available worldwide: a vaccine (Abrysvo, Pfizer) and a monoclonal antibody (nirsevimab, AstraZeneca and Sanofi Pasteur).

The Abrysvo vaccine is administered to mothers to give their babies protection against RSV infection. The Abrysvo vaccine is recommended for women at 32–36 weeks of pregnancy. In Poland, it is already available in pharmacies, at full price.

The monoclonal antibody nirsevimab (AstraZeneca and Sanofi Pasteur) is used in newborns and infants to protect against severe RSV infection. It is currently not available in Poland, although it is registered in Europe.

The paper presents current recommendations for the use of palivizumab (Synagis) in Poland, as well as current studies and recommendations from scientific societies and expert groups on the use of the Abrysvo vaccine and the monoclonal antibody nirsevimab (Beyfortus).

The paper also presents the rationale for the introduction of the health policy programme ”Nationwide health prevention programme: single passive immunisation with a monoclonal antibody for the prevention of lower respiratory tract infections caused by RS virus for 2025–2030”, submitted by the Polish Paediatric Society to the Ministry of Health in March 2024.
keywords:

respiratory syncytial virus, RSV, palivizumab, Abrysvo, nirsevimab

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.